Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Kensuke Kojima, Seiji Okada, Toshikazu Ushijima, Shinya Kimura, Eisaburo Sueoka

Blood (2020) 136 (7): 871–884.

https://doi.org/10.1182/blood.2019003084

Published: 2020

Includes: Supplemental data

Journal Articles

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Tatsuro Watanabe, PhD, Hiroshi Ureshino, MD, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Satoshi Yamashita, PhD, Toshikazu Ushijima, MD PhD, Seiji Okada, MD PhD, Eisaburo Sueoka, MD PhD, Shinya Kimura, MD PhD

Blood (2018) 132 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2018-99-117536

Published: 2018

Journal Articles

OR21, a New Oral DNA Methyltransferase Inhibitor for Treatment of MDS and AML

Hiroshi Ureshino, MD, Tatsuro Watanabe, PhD, Yuki Kurahashi, Yuki Fukuda Kurahashi, Kaoru Tohyama, MD, Seiji Okada, MD PhD, Toshikazu Ushijima, MD PhD, Hiroshi Ureshino, MD PhD

Blood (2018) 132 (Supplement 1): 5499.

https://doi.org/10.1182/blood-2018-99-112362

Published: 2018

Journal Articles

Genomics of Limited-Stage Diffuse Large B-Cell Lymphoma Developing Late Relapse: Analysis of Gene Alterations in Paired Primary and Late Relapsed Tumors By Target Sequencing

Tomotaka Suzuki, MD, Suguru Fukuhara, MD, Junko Nomoto, PhD, Satoshi Yamashita, PhD, Akiko Miyagi Maeshima, MD PhD, Yuta Ito, MD, Shunsuke Hatta, MD PhD, Sayako Yuda, MD PhD, Shinichi Makita, MD, PhD, Wataru Munakata, MD PhD, Tatsuya Suzuki, MD, PhD, Dai Maruyama, MD PhD, Hirokazu Taniguchi, MD, PhD, Toshikazu Ushijima, MD PhD, Koji Izutsu, MDPhD, Kensei Tobinai, MD PhD, Yukio Kobayashi, MDDSc

Blood (2018) 132 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2018-99-111262

Published: 2018

Journal Articles

Acquired loss of p53 induces blastic transformation in p210 bcr/abl -expressing hematopoietic cells: a transgenic study for blast crisis of human CML

Hiroaki Honda, Toshikazu Ushijima, Kuniko Wakazono, Hideaki Oda, Yuji Tanaka, Shin-ichi Aizawa, Takatoshi Ishikawa, Yoshio Yazaki, Hisamaru Hirai

Blood (2000) 95 (4): 1144–1150.

https://doi.org/10.1182/blood.V95.4.1144.004k04_1144_1150

Published: 2000

NARROW

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

OR21, a New Oral DNA Methyltransferase Inhibitor for Treatment of MDS and AML

Genomics of Limited-Stage Diffuse Large B-Cell Lymphoma Developing Late Relapse: Analysis of Gene Alterations in Paired Primary and Late Relapsed Tumors By Target Sequencing

Acquired loss of p53 induces blastic transformation in p210 bcr/abl -expressing hematopoietic cells: a transgenic study for blast crisis of human CML

Email alerts

ASH Publications

American Society of Hematology

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

OR21, a New Oral DNA Methyltransferase Inhibitor for Treatment of MDS and AML

Genomics of Limited-Stage Diffuse Large B-Cell Lymphoma Developing Late Relapse: Analysis of Gene Alterations in Paired Primary and Late Relapsed Tumors By Target Sequencing

Acquired loss of p53 induces blastic transformation in p210 bcr/abl -expressing hematopoietic cells: a transgenic study for blast crisis of human CML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only